Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$ITKH We are in .0038 FOlks. Lets Keep it moving NORTH!!!
$ITKH looking REAL GOOD!!!!
Thank you so much Roger!!!
Good Morning Sir
STROKE THAT PEN JOHNNY!!!
I been saying that for a while to a few peeps. Their are smarter people outside the community that can fix the dvr, movies, and channels. That got me a little on edge but hopefully things get better!!!!!!
Ok cool!!!!
who is fins?
GOOD MORNING BACK!!! AND YES WE ARE ALMOST THERE!!!
Ok thanks bro@!
ok thanks wormwood
Holding strong folks. Don't give up. will happen when we least expect it!!!
What you mean
Outstanding DD Prislea
Do your on dd but in my opinion yes!!!
Meaning???
Nice ??. Go $ITKH!!!
Good Morning Everyone. Let’s stay positive. Have a bless day. Go $ITKH!!
Hope so!!!
Good morning folks. Hope all is well
I looked again and it showed that from 2007 1:50. Stock split. Sorry on that. Bad info on stock tracker
Yes that’s what StockMaster says.
Stock Master shows a 1:50 Split. Is that correct? Anybody heard anything?
I agree oil. this is lovely lol. tempted to buy 2 million more to be honest
copy that sir
very very true
That’s where my range is. .05 will be good
ok that's cool. is everyone holding long on this stock or just looking to sell when it hits a penny or two??
Ok worm cool. when is the 2 year mark end. is it this year??
Hey is that a good thing?
Hoping and believing sir. Goes to nasdaq for a few dollars ??
yea worm I'm trying lol
Right on stock777777 :)))
I am so Sorry guys :((( I should have took my time and read through it more. it was posted in Itkh stock on stockstracker. please forgive me.
Rocket Pharmaceuticals and Iteknik Holding Corp (OTCMKTS:ITKH) Complete Merger Transaction
BIOTECH
January 19, 2018
Rocket Pharmaceuticals, Ltd., a major multi-platform gene therapy company in the U.S mainly enaged in addressing challenging rare diseases has announced that it has completed merging with Inotek Pharmaceuticals Corporation. The new company will now be called Rocket Pharmaceuticals Inc (NASDAQ:RCKT). Rocket will mainly focus on developing a pipeline of gene therapy programs that will mainly target undertreated and rare diseases. The company’s common stock will trade on NASDAQ under the symbol “RCKT”. Rocket has its headquarters in New York City and is headed by Gaurav Shah, M.D as the President and Chief Executive Officer. Before joining he worked as Global Program Head in the Cell & Gene Therapies Unit at Novartis.
In a statement, Dr. Shah said the transaction got a lot of support from both Inotek and Rocket shareholders. He added that this was a clear proof of the two companies’ long-term commitment to grow into a fully integrated multi-platform gene therapy company. He added that the completion of the merger will offer an opportunity to grow its operations, implement clinical development strategies and expand its manufacturing and analytics abilities. Dr. Shah added that they will be focusing more on driving the value of the new company.
Rocket uses a multi-platform development program that leverages the well-developed adeno-associated viral vector (AAV) and lentiviralvector (LVV) gene delivery methods and is currently targeting deadly rare diseases in children which lead to early mortality in the absence of bone marrow transplant.
The lead program of the company is a Phase 1/2 LVV-based gene therapy for Fanconi Anemia (FA) and is currently undergoing clinical studies with academic partners in Europe and the U.S. FA causes instability of the genetic system due to DNA mutations during gene repair leading to early bone marrow failure and malignancy. Initial results in people with FA have shown clinical engraftment of ex vivo-transduced autologous hematopoietic stem cells (HSCs). The rate of gene-corrected cells raise over time, indicating the selective advantage of gene-corrected cells in the bone marrow without the need for conditioning. Functional correction as well as clinical proof of idea have also been observed.
Investing News Center does not provide investment advice. See disclaimer.
JUST READ THE NEWS ON THE MERGER THAT WE JUST HAD!!!!!!!!!!
Well I’m buying the ask. I bought in at .0035 yesterday then somebody brought us down. Great job on whoever bought those 271000 shares yesterday. I bought another 200000
Good Morning Everybody. Have a great day :)))
Good morning everybody. Hope everyone had a great weekend:)